Lmcg Investments LLC Buys 866 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Lmcg Investments LLC lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 2.4% in the 3rd quarter, HoldingsChannel reports. The firm owned 37,703 shares of the biopharmaceutical company’s stock after buying an additional 866 shares during the quarter. Regeneron Pharmaceuticals accounts for 1.5% of Lmcg Investments LLC’s portfolio, making the stock its 11th biggest position. Lmcg Investments LLC’s holdings in Regeneron Pharmaceuticals were worth $28,589,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. BlackRock Inc. purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at about $5,682,636,000. Legal & General Group Plc bought a new position in Regeneron Pharmaceuticals in the second quarter worth about $473,872,000. Bank of New York Mellon Corp bought a new position in Regeneron Pharmaceuticals in the second quarter worth about $472,950,000. Deutsche Bank AG purchased a new stake in Regeneron Pharmaceuticals in the second quarter worth about $323,249,000. Finally, Man Group plc purchased a new stake in Regeneron Pharmaceuticals in the second quarter worth about $272,460,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Down 0.2%

NASDAQ:REGN opened at $805.67 on Thursday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. The firm’s 50-day moving average price is $791.56 and its 200-day moving average price is $722.18. The company has a market capitalization of $82.95 billion, a PE ratio of 19.91, a P/E/G ratio of 1.37 and a beta of 0.16. Regeneron Pharmaceuticals, Inc. has a 1-year low of $572.75 and a 1-year high of $859.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. During the same period last year, the company posted $12.81 EPS. Regeneron Pharmaceuticals’s revenue was up 16.7% on a year-over-year basis. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 48.87 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th were issued a $0.94 dividend. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date was Tuesday, August 18th. Regeneron Pharmaceuticals’s dividend payout ratio is 9.29%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, insider Andrew Murphy sold 4,147 shares of the business’s stock in a transaction that occurred on Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total value of $3,204,386.90. Following the sale, the insider directly owned 47,833 shares of the company’s stock, valued at $36,960,559.10. The trade was a 7.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Zoghbi sold 800 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $800.00, for a total value of $640,000.00. Following the completion of the sale, the director owned 1,703 shares in the company, valued at $1,362,400. The trade was a 31.96% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 8,093 shares of company stock worth $6,506,845 over the last three months. Company insiders own 6.97% of the company’s stock.

Analysts Set New Price Targets

Several research firms have weighed in on REGN. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, September 21st. Raymond James Financial increased their target price on Regeneron Pharmaceuticals from $902.00 to $911.00 and gave the stock an “outperform” rating in a research report on Friday, July 31st. The Goldman Sachs Group increased their target price on Regeneron Pharmaceuticals from $965.00 to $972.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Leerink Partners raised their target price on Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the company a “market perform” rating in a research note on Monday, August 17th. Finally, Evercore raised their target price on Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and eight have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $846.28.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses genetic and antibody-based research technologies to develop treatments in areas including eye diseases, allergic and inflammatory conditions, cancer, cardiovascular disease, infectious diseases and rare disorders.

Its marketed products include Eylea and Eylea HD for retinal diseases, Dupixent for several inflammatory and allergic conditions, Libtayo for certain cancers, Praluent for cardiovascular disease, Kevzara for rheumatoid arthritis, and other medicines such as Inmazeb, Evkeeza, Veopoz and Arcalyst.